TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05269147

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine Ganglion Block (SPGB)
Description: The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine Ganglion Block (SPGB)
Description: The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sphenopalatine Ganglion Block (SPGB)
Description: The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.
Study: NCT06642337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program +Oral Iron therapy
Description: The Nutritional Education Program is a structured intervention designed to enhance caregivers' understanding of nutrition and improve dietary practices for children suffering from iron deficiency anemia. The program comprises six weekly workshops lasting 1.5 hours each, focusing on essential topics such as the importance of iron in child development, identifying and preparing iron-rich foods, and practical meal planning strategies. Participants will engage in hands-on cooking demonstrations and receive educational materials, including recipe cards and meal planning tools, to support their learning. Knowledge assessments will be conducted at the beginning and end of the program to measure improvements in caregivers' nutritional knowledge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program +Oral Iron therapy
Description: The Nutritional Education Program is a structured intervention designed to enhance caregivers' understanding of nutrition and improve dietary practices for children suffering from iron deficiency anemia. The program comprises six weekly workshops lasting 1.5 hours each, focusing on essential topics such as the importance of iron in child development, identifying and preparing iron-rich foods, and practical meal planning strategies. Participants will engage in hands-on cooking demonstrations and receive educational materials, including recipe cards and meal planning tools, to support their learning. Knowledge assessments will be conducted at the beginning and end of the program to measure improvements in caregivers' nutritional knowledge.
Study: NCT05425641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?
Study: NCT05250401

Intervention type: DIAGNOSTIC_TEST
Intervention: liver functions and thyroid functions
Description: laboratory tests

Intervention type: DIAGNOSTIC_TEST
Intervention: liver functions and thyroid functions
Description: laboratory tests
Study: NCT04886258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFV890
Description: DFV890

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05587244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
Description: Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
Study: NCT06289504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered as a single dose orally 2 times during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin will be administered as a single dose orally 2 times during the study.
Study: NCT05256706

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SomaSignal Informed Medical Management SSCVD
Description: For participants randomized to the Informed arm, the SSCVD test results will be provided to the participant's clinicians approximately 2-4 weeks after the baseline blood draw. Clinicians will discuss results with the participant and make adjustments to the care plan as needed based on the SSCVD test results within 50 days of receiving results. Clinicians may advise participants to (i) either change the doses of existing medications within existing guidelines, (ii) prescribe additional guideline-based medications, (iii) advise additional lifestyle interventions, or (iv) advise no change. This information will be documented in the case report forms. This test is neither intended to diagnose cardiovascular disease (CVD) nor replace the standard of care protocols for this disease. The physician should not rely solely on this information to make a decision on the best course of action for this patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Clinicians will provide the standard of care based on routine test results and without the SSCVD results. The SSCVD and SomaSignal Metabolic Factor Panel results from participants from both the baseline and 6-month period will be provided to the study team at the 6-month study visit. The SomaSignal Metabolic Factor tests include evaluation of Liver Fat, Glucose Tolerance, Kidney Function, Alcohol Impact, Cardiorespiratory Fitness/oxygen consumption (VO2) max, Resting Energy Rate, Body Fat Percentage, Visceral Fat, and Lean Body Mass. Any recommendations made to the participant by the physicians, based on obtaining the aforementioned test results will be collected.
Study: NCT05289661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Ripasudil
Description: To determine the effect of rho-kinase inhibitors on endothelial cell loss

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Ripasudil
Description: To determine the effect of rho-kinase inhibitors on endothelial cell loss

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo
Description: topical Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo
Description: topical Placebo
Study: NCT05766735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care + Glycemic Excursion Minimization (RC+GEM)
Description: In addition to receiving routine care, participants will receive GEM, a structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care (RC)
Description: RC participants will meet with their primary care provider to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
Study: NCT05379595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Fluorouracil will be administered as intravenous infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Fluorouracil will be administered as intravenous infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin will be administered as intravenous infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin will be administered as intravenous infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as intravenous infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan will be administered as intravenous infusion.
Study: NCT06299540

Intervention type: BEHAVIORAL
Intervention: Individual Physical Activity Intervention (IPAI)
Description: No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.

Intervention type: DRUG
Intervention: Ibrutinib
Description: No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.

Intervention type: DRUG
Intervention: Ibrutinib
Description: No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
Study: NCT05182827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Description: The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Description: The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness.
Study: NCT06556940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMN-401
Description: Orally delivered tablets and capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMN-401
Description: Orally delivered tablets and capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMN-401
Description: Orally delivered tablets and capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMN-401
Description: Orally delivered tablets and capsules
Study: NCT05957536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D3L-001
Description: Intravenous administration
Study: NCT05071664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as a SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab
Description: Guselkumab will be administered as a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered as a SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a SC injection.
Study: NCT04779918

Intervention type: DEVICE
Group type: OTHER
Intervention: OviTex Reinforced Tissue Matrix
Description: All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
Study: NCT06049017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally.
Study: NCT06260163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Subcutaneous
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Subcutaneous
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Subcutaneous
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Subcutaneous
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Intravenous
Description: Guselkumab will be administered intravenously.
Study: NCT04064164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speeko for Elderspeak
Description: Speeko for Elderspeak is a communication feedback IOS application.
Study: NCT06059339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
Description: Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
Description: Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
Description: Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
Study: NCT05862285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy and in combination with tiragolumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy and in combination with tiragolumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Study: NCT06489106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity based upper extremity training with and without stimulation
Description: Activity-based upper extremity training (AB-UET) will be administered 5d/week and 1 hour 30 minutes/session. For AB-UET+ stimulation (scTS), UE tasks will be repeated with and without scTS so that scTS is administered intermittently for the duration of \~ 10 minute/bouts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity based upper extremity training with and without stimulation
Description: Activity-based upper extremity training (AB-UET) will be administered 5d/week and 1 hour 30 minutes/session. For AB-UET+ stimulation (scTS), UE tasks will be repeated with and without scTS so that scTS is administered intermittently for the duration of \~ 10 minute/bouts.
Study: NCT06045663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laminectomy without lateral mass fixation
Description: patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laminectomy with lateral mass fixation
Description: patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
Study: NCT06179069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1310
Description: Drug: ZL-1310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1310
Description: Drug: ZL-1310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1310
Description: Drug: ZL-1310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1310
Description: Drug: ZL-1310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1310
Description: Drug: ZL-1310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1310
Description: Drug: ZL-1310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Drug Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Drug Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Drug Carboplatin
Study: NCT04943042

Intervention type: DRUG
Intervention: Avatrombopag
Description: According to prescription